Gene Sequencing in Newborn Screening: Covering the Bases of Education and Follow-Up. Amy Gaviglio, MS, CGC February 17, 2017

Similar documents
Development of a Multiplex CYP21A2 Genotyping Assay for Congenital Adrenal Hyperplasia Screening

Sequencing in Newborn Screening Introduction and Background

Screen Positive Follow-up In The Clinic

Counsyl Foresight Carrier Screen. Utmost confidence in every result

Long-term Follow-up for Cystic Fibrosis: A Collaboration with the Cystic Fibrosis Foundation

CYP21A2 Mutations Found in Congenital Adrenal Hyperplasia Patients in the California Population

An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers

Improving Communication of Negative Newborn Screening Results. Whitney Thompson MPhil Amy Gaviglio MS, CGC Susan Berry MD

Talking Genomes with Your Patients. Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology

CYSTIC FIBROSIS. The condition:

Compound heterozygosity Yurii S. Aulchenko yurii [dot] aulchenko [at] gmail [dot] com. Thursday, April 11, 13

History of Screening for CF and CH in New Zealand. Dianne Webster Diane Casey Kathy Bendikson Richard MacKay Paul Hofman

Lab Activity Report: Mendelian Genetics - Genetic Disorders

Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form

Diagnostic challenges after NBS for CF

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

Cover Page. The handle holds various files of this Leiden University dissertation.

TEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647

Introduction to Genetics

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation

THE JOURNAL OF PEDIATRICS

Newborn Screening for Cystic Fibrosis

Multi-Center Feasibility Study of a Neonatal IRT-PAP Screening Concept for Cystic Fibrosis

Newborn Screening for Cystic Fibrosis in Switzerland - Evaluation after two years

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation. Chris Miller, MS, LCGC ARUP Laboratories

Median Normalization of Newborn Screening Analyte Data to Improve Screening Performance

Introduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center

Corporate Medical Policy

2/3 x 1 x 1/4 = 2/12 = 1/6

Evening Case studies, Tuesday April 30, Vijay L. Grey McMaster University

Annual Report Calendar Year 2015

Cystic Fibrosis a) Diagnostic Dilemmas b) The New Problems. Dr Mark Rosenthal Royal Brompton Hospital London

Human Genetic Disorders

Extra Review Practice Biology Test Genetics

FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

Introduction to LOH and Allele Specific Copy Number User Forum

Benefits and pitfalls of new genetic tests

Population Screening for Fragile X Syndrome

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Early Intervention: The Importance of Newborn Screening

DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

A guide to understanding variant classification

Challenges of CGH array testing in children with developmental delay. Dr Sally Davies 17 th September 2014

Genetic Disorders. Students must provide an explanation for all problems. Students must have parent signature prior to submission.

What You ll Learn. Genetics Since Mendel. ! Explain how traits are inherited by incomplete dominance

GENETIC TESTING WITH MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES

SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.

Ch 7 Extending Mendelian Genetics

TIMELINESS IN NEWBORN SCREENING: CONSIDERATIONS FOR CYSTIC FIBROSIS

GENETIC TESTING FOR TAMOXIFEN TREATMENT

Human Genetic Disorders. Lesson Overview. Lesson Overview Human Genetic Disorders

Questions Q1. ) in the box next to your answer. (1) A FF B Ff C ff. D ff (ii) Explain why a person with cystic fibrosis (CF) may lose body mass.

certain genotypes known to be associated with genetic disease or a predisposition to genetic disease

Sequencing. Deletion/Duplication Analysis. How Does Genetic Testing for Cancer Work?

The Six Ws of DNA testing A scenario-based activity introducing medical applications of DNA testing

The study of hereditary traits

Attachment 1. Newborn Screening Program Description

Golden Helix s End-to-End Solution for Clinical Labs

American Psychiatric Nurses Association

Should Universal Carrier Screening be Universal?

Lesson Overview. Human Genetic Disorders. Lesson Overview Human Genetic Disorders

Cystic Fibrosis Carrier Testing

Sequencing studies implicate inherited mutations in autism

Saving Lives Through Newborn Screening: Making the Most of a Simple Blood Test

GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

NEONATAL SCREENING FOR CYSTIC FIBROSIS. PAST AND FUTURE. Pilot Study and RECENT INFORMATION EVA PCMA vzw Antwerp-Belgium.

Documentation of Changes to EFI Standards: v 5.6.1

PRE-PREGNANCY CARRIER SCREENING. What is it, how does it work and should future parents consider it?

Newborn Bloodspot Screening Information for parents

Patterns of Heredity Genetics

A Quick Guide to the. I507del. Mutation CFTR SCIENCE

Evaluation of Patients with Diffuse Bronchiectasis

Newborn Bloodspot Screening Information for parents

Cystic Fibrosis. Presented by: Chris Belanger & Dylan Medd

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER

Guided Notes: Simple Genetics

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

NOTES: : HUMAN HEREDITY

UK Newborn Screening for X-ALD - progress from a lab perspective

Long Term Follow-Up Clinical Guidelines for X-linked Adrenoleukodystrophy

Lesson Overview. Human Genetic Disorders. Lesson Overview Human Genetic Disorders

Two copies of each autosomal gene affect phenotype.

Testing for Genetic Disorders that Cause Brain Damage

Patterns of Inheritance

PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM

MULTIPLE CHOICE QUESTIONS

Developmental Psychology 2017

What is the inheritance pattern (e.g., autosomal, sex-linked, dominant, recessive, etc.)?

ICARE Initiative. Cristi Radford, MS, CGC ICARE Outreach Coordinator

Disclosures. Learning Objectives. What is Cystic Fibrosis? Background

RAZAN AL-ZOUBI. Farah Albustanji BELAL AZAB. 1 P a g e

B1 Question 1 Foundation

GENETIC TESTING: IN WHOM AND WHEN

PATIENT EDUCATION. Cystic Fibrosis Carrier Testing

Genetics and Genetic Testing for Autism:

Medical Genetics. Consult and Referral Guidelines

Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016

For the Ongoing Management of Babies under 1 year old.

Transcription:

Gene Sequencing in Newborn Screening: Covering the Bases of Education and Follow-Up Amy Gaviglio, MS, CGC February 17, 2017

Outline Education Personnel Case Examples Considerations

EDUCATION: OUR BASELINE

Health Literacy where are we? Only 12% of adults have proficient health literacy 1 Affects all races and ethnicities; though some more than others Almost 10% of the US population is considered Limited English Proficient 2 1 National Assessment of Adult Literacy; 2 Migration Policy Institute

Genetic Health Information Often derived from television House, CSI, Gray s Anatomy, etc. Misconceptions Timeliness Absoluteness High expectations of capabilities

Current State of Newborn Screening Education The PKU Test lives on Low understanding of what screening is and is not Programs rely on providers as mouthpieces Variable success pre- and post-analytically

EDUCATION: FUTURE STATE

Gene Sequencing: General Education Awareness of genetic exceptionalism Hesitancy around genetic testing BabySeq experience Knowledge is Power But Ignorance is Bliss

Gene Sequencing: Education of Providers before Starting Physicians indicate an overall lack of knowledge and confidence in discussing genetic risk 1 Newborn screening-specific needs: Still requires 1 st tier false negatives still possible Whether carrier status will be reported and how Will notification be made on biochemical result while DNA pending 1 Mikat-Stevens, et al., Genetics in Medicine (2015) 17, 169-176

Gene Sequencing: Pre-Analytical Education Likely largely unchanged Methodologies not typically discussed Need to discuss increased possibility of detecting carrier status/ambiguous results Dependent upon reporting paradigm Prior awareness of NBS makes abnormal result reporting easier

Gene Sequencing: Post-Analytical Education What do we know about specific variants found Need to confirm molecular results clinically Mixed thoughts on this Genotype does not always dictate phenotype Will need other diagnostic testing as well

Gene Sequencing: Post-Analytical Education How to communicate to parents Risk communication Genetic information Difference between carrier and disease states Implications for other family members

PERSONNEL NEEDS

The Follow-Up Team Need for staff comfortable in discussing genetic information with providers (and parents) Inheritance Phasing Deletions, duplications, conversions, point s Homozygosity, heterozygosity

The Follow-Up Team Importance of communication between lab, follow-up, and sub-specialists Work together to determine and update variant interpretations Responsibility to check databases? Increased importance to participate in long-term registries to help characterize variants

Notification and Follow-Up Protocol Likely will need to change: More important to talk directly with primary care provider (avoid telephone game) Consider fax of information first Development of follow-up protocols for VUS s Need standardization amongst programs Unified genetic nomenclature

CASE EXAMPLES: THE SIMPLE, COMPLEX, AND DOWNRIGHT CRAZY

Simple Case Example: Cystic Fibrosis Elevated IRT (281.1 ng/ml) followed by DNA Shows homozygous ΔF508 ΔF508 Known CF-causing allele with likely pancreatic insufficiency Enzymes should be started as soon as possible with sweat test confirmation < 4 wks of age

Complex Case Example: Cystic Fibrosis Elevated IRT (67 ng/ml) followed by DNA Het for 2 variants: S1255X (ex. 19) and S1255X (ex. 20) CFTR2 indicates that S1255X (ex. 20) causes CF when found with another CF-causing variant S1255X (ex. 19) not listed How should this result be handled?

Complex Case Example: Cystic Fibrosis Treat as ONE variant: S1255X (ex. 19) and S1255X (ex. 20) act as a haplotype Enzymes don t need to be started Sweat test results = 4 and 5 mmol/l

Complex Case Example: Cystic Fibrosis Elevated IRT ( 62 ng/ml) followed by DNA Het for 2 variants: ΔF508 and L32M Initial sweat test <60 mmol/l CRMS designation Conversion can occur (both in sweat test and fecal elastase) Repeat sweat test now >60mmol/L Now meets Classic CF diagnostic criteria CF relies on much more than genotype for diagnosis CRMS represents a diagnostic odyssey 1 Salinas, et al., PLOS ONE (2016) 11(5)

Case Example: CAH CAH has relatively high FPR and FNR molecular testing appealing CYP21A2 gene in chromosomally complex region 30kb deletion, gene conversion, pseudogene, etc. Phenotype is typically dictated by the less severe of the two variants

Case Example: CAH Due to complex region, multiple variants are common (~13% in MN population) CAH-0028: 8 variants found Homozygous I727N; homozygous V281L, het I236N, het V238E, het M239K, het L307fs

Case Example: CAH Phasing exceedingly important to understand configuration of variants! I172N V281L I172N I236N V238E M239K V281L L307fs

Case Example: CAH What is the phenotype? Patient actually has SW CAH due to NC variants being in cis with other variants SV NC I172N V281L I172N I236N V238E M239K V281L L307fs SV SW NC SW

X-ALD: A Discussion X-linked disorder affecting primarily males Most females will show symptoms later in life Between 4.1% and 19% de novo rate 1 No relevant genotype-phenotype correlation Addison s disease only Adrenomyeloneuropathy Celebral X-ALD 1 Wiesenger, et al., Appl Clin Genet (2015) 8, 109-121

X-ALD: A Discussion >700 known variants; increasing likelihood of detecting VUS Genotype does not affect treatment or management May help distinguish X-ALD from other peroxisomal disorders

FUTURE CONSIDERATIONS

Gene Sequencing Education and Follow-Up: Challenges Ever increasing need to educate providers Understanding of sequencing technology Understanding of genetic terms and implications Expanded role of primary care in ongoing monitoring for ambiguous/late-onset results

Gene Sequencing Education and Follow-Up: Challenges Need to ensure prepared follow-up workforce Ensuring variant information reaches providers In states with few clinical Genetic Counselors, will programs need to take this on? Ambiguity and extended follow-up when is a diagnosis complete?

Gene Sequencing Follow-Up and Education: Opportunities Newborn Screening-specific: Potential for earlier diagnosis Potential for more appropriate treatment or avoidance of inappropriate treatments Potential for lower FPR and FNR

Gene Sequencing Follow-Up and Education: Opportunities Contribute to knowledge and understanding Addressing health equity and access Don t need pre-authorizations Provides potentially needed information to families who might otherwise not be able to afford it

How does the addition of gene sequencing contribute to the mission of NBS? What is the impact to the SYSTEM of adding gene sequencing To affected To unaffected To unknown

Thank You Sarah Bradley Marilyn Erickson Aaron Goldenberg Cindy Lorentz Beth Tarini Beth Vogel